Suscribirse

CYSTINE CALCULI : Diagnosis and Management - 11/09/11

Doi : 10.1016/S0094-0143(05)70361-X 
Scott D. Rutchik, MD *, Martin I. Resnick, MD *

Resumen

It has been nearly two centuries since Wollaston78 first described the presence of an unusual chemical component in bladder calculi, which he termed cystic oxide. Observing the absence of an oxide moiety, Berzelius3 renamed the compound cystine, but it was not until 1902 that Friedman23 finally elucidated the chemical structure of cystine. Cystinuria is recognized today as the excessive excretion into the urine of the four basic amino acids cystine, lysine, ornithine, and arginine (Figure 1). Of these, only cystine is relatively insoluble at ordinary urinary pHs.74 Patients afflicted with cystinuria produce a supersaturated urine and are at risk for cystine crystallization and stone formation. For this reason, the only phenotypically important feature of cystinuria is the predisposition toward calculi in the urinary tract. Nutritional deficiencies of the essential dibasic amino acids lysine and arginine do not occur in cystinurics because the jejunal enzymatic defect responsible for their transport as monomers does not affect their absorption in dipeptide form.32, 66

Overall, cystine stones represent 1% to 2% of urinary calculi.42, 50 The worldwide prevalence of homozygous cystinuria varies considerably, affecting 1 per 15,000 persons in the United States but as many as 1 in 2500 Jews of Libyan extraction51, 77; furthermore, it is a clinically important source of stone disease in children, accounting for 6% to 8% of pediatric urinary calculi.48, 55 In their series of cystinuric patients during a 14-year follow-up, Linari et al43 showed that stone disease occurred at a rate of 1.22 stone episodes per patient per year; therefore, the majority of cystinurics will suffer recurrent stone disease during their lifetimes.

Much attention has been directed toward improved means of diagnosis, prevention, and treatment of patients with cystine lithiasis, and current treatment strategies of cystine calculi may entail a multimodal approach. Advances in minimally invasive stone destruction and chemoprevention have given the urologist a sophisticated and often challenging armamentarium in the treatment of these patients. This article reviews the relevant pathophysiology of cystine calculus disease as well as techniques used in its diagnosis. Current medical and surgical techniques used in prevention and treatment also are reviewed.

El texto completo de este artículo está disponible en PDF.

Esquema


 Address reprint requests to Martin I. Resnick, MD, Department of Urology, University Hospitals of Cleveland, 11100 Euclid Avenue, Cleveland, OH 44106–5046


© 1997  W. B. Saunders Company. Publicado por Elsevier Masson SAS. Todos los derechos reservados.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 24 - N° 1

P. 163-171 - février 1997 Regresar al número
Artículo precedente Artículo precedente
  • TREATMENT OPTIONS IN STRUVITE STONES
  • Lester P. Wang, Hoo Yin Wong, Donald P. Griffith
| Artículo siguiente Artículo siguiente
  • PEDIATRIC UROLITHIASIS
  • R. Lawrence Kroovand

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

¿Ya suscrito a @@106933@@ revista ?

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2025 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.